ENGAGE vs CardioGenetics

Disclaimer: This app is only for participants in the ENGAGE-HF research study.Disclaimer: This app is only for participants in the ENGAGE-HF research study. Welcome to ENGAGE-HF, your personalized heart health companion! Developed by Stanford University using the Stanford Spezi framework in collaboration with the DOT HF network, funded by the American Heart Association Health Tech SFRN, this app is designed to make managing heart failure easier and more effective. With ENGAGE-HF, you have the power to optimize your heart failure treatment plan and improve your overall well-being. Our app simplifies the process of getting the best combination of medicines to help you live longer and healthier. By tracking your vitals and health status over time, you'll be more engaged in your heart failure care, allowing for personalized interventions and better health outcomes. Your heart health journey begins with the main dashboard, where you'll find daily check-ins and two-week check-ins, closely monitoring your heart health. During your daily check-in, you'll provide vital health status information, and the app will help you track your medication adherence, giving you valuable insights into your progress. We encourage active participation in your heart health management, and to motivate you further, ENGAGE-HF features an engagement score. By completing app activities, like answering daily health status questions, reporting medication adherence, and checking vitals, you'll increase your score, empowering you to stay on track. Inside the app, you'll discover three main pages: Vitals, Health Status, and Medication. The Vitals page lets you view your blood pressure, heart rate, and weight measurements. On the Health Status page, we utilize the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12), the dizziness questionnaire, and the daily health status question, giving you a comprehensive view of your heart failure symptoms and overall well-being. The Medication page offers detailed information about your core heart failure medications. The Health Summary feature presents a comprehensive overview of vitals, health status scores, and medications, empowering you to prepare questions for your clinicians. Easily share a PDF summary with healthcare providers or caregivers, fostering collaborative care. The ENGAGE-HF app offers short educational videos to deepen your understanding of heart failure management. Learn about app usage, heart failure medications, and monitoring from expert insights provided by the American Heart Association and the Heart Failure Society of America. Get ready to empower your heart health with ENGAGE-HF! Start your journey to a healthier and happier life. Download the app now and take charge of your heart failure management!

Every inherited cardiomyopathy evaluation warrants meticulous, accurate, and evidence-based risk stratification. CardioGenetics compiles validated calculators, diagnostic frameworks, and a live clinical trial finder in your pocket. USED AT THE BEDSIDE Whether you are presenting at a multidisciplinary cardiomyopathy board, interpreting a new pathogenic variant, or seeing your first LMNA patient, CardioGenetics gives the same tools with the evidence and models behind every number. ASCVD RISK ALIGNED WITH THE 2026 GUIDELINES Calculate 10-year risk with AHA PREVENT (ages 30–79), compare against the legacy Pooled Cohort Equations, integrate coronary artery calcium via the MESA score, and interpret Lipoprotein(a) with a built-in risk multiplier. Every result maps directly to the 2026 ACC/AHA dyslipidemia guideline statin thresholds, risk-enhancing factors, and CAC decision pathways. GENE-SPECIFIC SUDDEN CARDIAC DEATH RISK Not all cardiomyopathies carry the same arrhythmic risk. CardioGenetics includes dedicated calculators for HCM (ESC 2014 Risk-SCD), ARVC (Cadrin-Tourigny), LMNA (Wahbi, ESC 2023-adapted), PLN p.Arg14del (Verstraelen), DSP (ERADOS, Eur Heart J 2024), FLNC (Gigli, JAMA Cardiol 2025), and PKP2-specific guidance. Each cross-referenced to the latest ESC 2023 and AHA/ACC 2024 guidelines. DIAGNOSTIC FRAMEWORKS AT YOUR FINGERTIPS Confirm diagnoses before you risk-stratify. Built-in criteria include the 2020 Padua Criteria for arrhythmogenic cardiomyopathy, AHA/ACC 2024 and ESC 2023 HCM diagnostic standards, LVNC scoring (Jenni, Petersen, Stöllberger), and DCM phenotyping. FIND THE RIGHT CLINICAL TRIAL Browse actively enrolling studies for Lp(a), HCM, ACM/ARVC, DSP, LMNA, and PLN with interactive U.S. state and European enrollment maps. Every trial includes its NCT identifier and a direct link to ClinicalTrials.gov. DESIGNED FOR WHAT WE ACTUALLY DO IN CLINIC • Search any calculator, diagnosis, or trial from a single search bar • Tap a risk score and see the full mathematical model, original citation, and DOI • View sensitivity analyses and interactive risk curves • Share lay-language summaries during patient-facing discussions • Cross-navigate between diagnostic confirmation and risk stratification in one tap TRUST BUT VERIFY: Every calculator reproduces its published equation with full variable definitions and baseline coefficients. There are no "black boxes" here, no proprietary modifications. Tap any citation to access the original published manuscript. INTENDED USERS: Cardiologists · Electrophysiologists · Genetic Counselors · Cardiology Fellows and Residents · Medical Students · Advanced Practice Providers · Inherited Cardiovascular Disease Teams Developed by Mark E. Pepin, MD, PhD, FESC. All risk models are derived from peer-reviewed literature and their original sources. This app is a clinical decision-support aid for healthcare professionals and does not replace clinical judgment, institutional protocols, or shared decision-making. Not FDA-cleared or CE-marked.